The prognosis (likely outcome of a disease) varies widely in patients with myelofibrosis (MF). Each patient’s prognostic risk factors are evaluated individually. It is important to know that outcome data can show how groups of people with MF responded to treatment, but data cannot always determine how any one person will respond. Median survival for MF patients is approximately
- 15.4 years for low-risk patients
- 6.5 years for INT (intermediate)-1risk patients
- 2.9 years for INT-2 risk patients
- 1.3 years for high-risk patients
Some people, however, may survive for decades following a diagnosis. For these reasons, patients are advised to discuss survival information with their doctors.
- Download or order The Leukemia & Lymphoma Society’s free booklet, Myeloproliferative Neoplasms